Robert Durrans
Family Medicine · Orem, UTNPI 1447332465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 29.3% of the total. Reporting peaked in 2021 at $894 and has fallen 60.8% since, to $351 in 2025.
Across 236 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$379
- Lilly USA, LLC$355
- AstraZeneca$318
- Takeda Pharmaceuticals U.S.A., Inc.$218
- Teva Pharmaceuticals USA, Inc.$208
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,800100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,112 |
| Boehringer Ingelheim | 23 | $379 |
| Lilly USA, LLC | 22 | $355 |
| AstraZeneca | 19 | $318 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $218 |
| Teva Pharmaceuticals USA, Inc. | 19 | $208 |
| Merck | 9 | $141 |
| Corium, LLC | 9 | $140 |
| Abbott | 7 | $114 |
| Pfizer | 5 | $98 |
| Alfasigma USA, Inc. | 6 | $84 |
| Novo Nordisk | 4 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Zyla Life Sciences, Inc. | 3 | $40 |
| Lundbeck LLC | 2 | $33 |
| Biomerieux Inc | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Bayer | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Shield Therapeutics Inc | 1 | $20 |
| Medtronic | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Mckesson Medical-surgical, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$3,800 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 11 | $334 |
| Pantoprazole Sodium | 11 | $286 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Orem
- Jeremy ReidOrem$8K
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.